Search

Your search keyword '"Bunworasate U"' showing total 12 results
Start Over Author "Bunworasate U" Search Limiters Full Text
12 results on '"Bunworasate U"'

1. Advances in hematopoietic stem cell transplantation in the Asia-Pacific region: the second report from APBMT 2005–2015

Author

Bunworasate U, Huynh Vm, Lie Akw, Alok Srivastava, Baylon H, Akter Mr, Minako Iida, Lallindra Gooneratne, Hye Jin Kang, Jih-Luh Tang, Yoshihisa Kodera, Ong Tc, Ho Ayl, Yoshiko Atsuta, A. Ghavamzadeh, Gyi Aa, S. Okamoto, Wu T, Ian Nivison-Smith, Anthony J. Dodds, and Farzana T

Subjects
Male, Pediatrics, medicine.medical_specialty, Asia, Transplantation Conditioning, medicine.medical_treatment, Population, Hematopoietic stem cell transplantation, Asia pacific region, History, 21st Century, 03 medical and health sciences, 0302 clinical medicine, Humans, Medicine, education, Retrospective Studies, Transplantation, education.field_of_study, Absolute number, business.industry, Incidence (epidemiology), Hematopoietic Stem Cell Transplantation, Correction, Hematology, medicine.disease, surgical procedures, operative, Hemoglobinopathy, 030220 oncology & carcinogenesis, Cord blood, Allogeneic hsct, Female, business, 030215 immunology
Abstract

Between 2005 and 2015, 138,165 hematopoietic stem cell transplantation (HSCT) were reported in 18 countries/regions in the Asia-Pacific region. In this report, we describe current trends in HSCT throughout the Asia-Pacific region and differences among nations in this region and various global registries. Since 2008, more than 10,000 HSCTs have been recorded each year by the Asia-Pacific Blood and Marrow Transplantation Group Data Center. Between 2005 and 2015, the greatest increase in the number of HSCTs was observed in Vietnam. Allogeneic HSCT was performed more frequently than autologous HSCT, and a majority of cases involved related donors. Regarding allogeneic HSCT, the use of cord blood has remained steady, especially in Japan, and the number of cases involving related HLA non-identical donors has increased rapidly, particularly in China. The incidence of hemoglobinopathy, a main indication for allogeneic HSCT in India, China, Iran, and Pakistan, increased nearly six-fold over the last decade. Among the 18 participating countries/regions, the transplant rate per population varied widely according to the absolute number of HSCTs and the national/regional population size. We believe that this report will not only benefit the AP region but will also provide information about HSCT to other regions worldwide.

Published
2019
Full Text
View/download PDF

5. PS1077 EVENT FREE SURVIVAL AT 12 MONTHS AND 24 MONTHS AS PREDICTORS FOR OUTCOME OF SYSTEMIC PERIPHERAL T CELL LYMPHOMA: ANALYSIS OF NATIONWIDE THAI LYMPHOMA STUDY GROUP

Author

Wudhikarn, K., primary, Bunworasate, U., additional, Julamanee, J., additional, Lekhakula, A., additional, Ekwattanakit, S., additional, Khuhapinant, A., additional, Norasetthada, L., additional, Nawarawong, W., additional, Laoruangroj, C., additional, Numbenjapon, T., additional, Niparuck, P., additional, Chancharunee, S., additional, Kanitsap, N., additional, Wongkhatee, S., additional, Makruasi, N., additional, Wong, P., additional, Sirijerachai, C., additional, Chansung, K., additional, Suwanban, T., additional, Praditsuktavorn, P., additional, and Intragumtornchai, T., additional

Published
2019
Full Text
View/download PDF

8. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival

Author

Hartwell, M. J., Ozbek, U., Holler, E., Renteria, A. S., Major-Monfried, H., Reddy, P., Aziz, M., Hogan, W. J., Ayuk, F., Efebera, Y. A., Hexner, E. O., Bunworasate, U., Qayed, M., Ordemann, R., Wolfl, M., Mielke, S., Pawarode, A., Chen, Y. -B., Devine, S., Harris, A. C., Jagasia, M., Kitko, C. L., Litzow, M. R., Kroger, N., Locatelli, Franco, Morales, G., Nakamura, R., Reshef, R., Rosler, W., Weber, D., Wudhikarn, K., Yanik, G. A., Levine, J. E., Ferrara, J. L. M., Locatelli F. (ORCID:0000-0002-7976-3654), Hartwell, M. J., Ozbek, U., Holler, E., Renteria, A. S., Major-Monfried, H., Reddy, P., Aziz, M., Hogan, W. J., Ayuk, F., Efebera, Y. A., Hexner, E. O., Bunworasate, U., Qayed, M., Ordemann, R., Wolfl, M., Mielke, S., Pawarode, A., Chen, Y. -B., Devine, S., Harris, A. C., Jagasia, M., Kitko, C. L., Litzow, M. R., Kroger, N., Locatelli, Franco, Morales, G., Nakamura, R., Reshef, R., Rosler, W., Weber, D., Wudhikarn, K., Yanik, G. A., Levine, J. E., Ferrara, J. L. M., and Locatelli F. (ORCID:0000-0002-7976-3654)

Published
2017

9. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium

Author

Harris, A. C., Young, R., Devine, S., Hogan, W. J., Ayuk, F., Bunworasate, U., Chanswangphuwana, C., Efebera, Y. A., Holler, E., Litzow, M., Ordemann, R., Qayed, M., Renteria, A. S., Reshef, R., Wolfl, M., Chen, Y. -B., Goldstein, S., Jagasia, M., Locatelli, Franco, Mielke, S., Porter, D., Schechter, T., Shekhovtsova, Z., Ferrara, J. L. M., Levine, J. E., Locatelli F. (ORCID:0000-0002-7976-3654), Harris, A. C., Young, R., Devine, S., Hogan, W. J., Ayuk, F., Bunworasate, U., Chanswangphuwana, C., Efebera, Y. A., Holler, E., Litzow, M., Ordemann, R., Qayed, M., Renteria, A. S., Reshef, R., Wolfl, M., Chen, Y. -B., Goldstein, S., Jagasia, M., Locatelli, Franco, Mielke, S., Porter, D., Schechter, T., Shekhovtsova, Z., Ferrara, J. L. M., Levine, J. E., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Acute graft-versus-host disease (GVHD) remains a leading cause of morbidity and nonrelapse mortality after allogeneic hematopoietic cell transplantation. The clinical staging of GVHD varies greatly between transplant centers and is frequently not agreed on by independent reviewers. The lack of standardized approaches to handle common sources of discrepancy in GVHD grading likely contributes to why promising GVHD treatments reported from single centers have failed to show benefit in randomized multicenter clinical trials. We developed guidelines through international expert consensus opinion to standardize the diagnosis and clinical staging of GVHD for use in a large international GVHD research consortium. During the first year of use, the guidance followed discussion of complex clinical phenotypes by experienced transplant physicians and data managers. These guidelines increase the uniformity of GVHD symptom capture, which may improve the reproducibility of GVHD clinical trials after further prospective validation.

Published
2016

12. Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program

Author

Sruamsiri Rosarin, Chaiyakunapruk Nathorn, Pakakasama Samart, Sirireung Somtawin, Sripaiboonkij Nintita, Bunworasate Udomsak, and Hongeng Suradej

Subjects
Cost-utility analysis, Reduced intensity transplantation, Thalassemia, Adolescence, Adult, Public aspects of medicine, RA1-1270
Abstract

Abstract Background Hematopoieticic stem cell transplantation is the only therapeutic option that can cure thalassemia disease. Reduced intensity hematopoietic stem cell transplantation (RI-HSCT) has demonstrated a high cure rate with minimal complications compared to other options. Because RI-HSCT is very costly, economic justification for its value is needed. This study aimed to estimate the cost-utility of RI-HSCT compared with blood transfusions combined with iron chelating therapy (BT-ICT) for adolescent and young adult with severe thalassemia in Thailand. Methods A Markov model was used to estimate the relevant costs and health outcomes over the patients’ lifetimes using a societal perspective. All future costs and outcomes were discounted at a rate of 3% per annum. The efficacy of RI-HSCT was based a clinical trial including a total of 18 thalassemia patients. Utility values were derived directly from all patients using EQ-5D and SF-6D. Primary outcomes of interest were lifetime costs, quality adjusted life-years (QALYs) gained, and the incremental cost-effectiveness ratio (ICER) in US ($) per QALY gained. One-way and probabilistic sensitivity analyses (PSA) were conducted to investigate the effect of parameter uncertainty. Results In base case analysis, the RI-HSCT group had a better clinical outcomes and higher lifetime costs. The incremental cost per QALY gained was US $ 3,236 per QALY. The acceptability curve showed that the probability of RI-HSCT being cost-effective was 71% at the willingness to pay of 1 time of Thai Gross domestic product per capita (GDP per capita), approximately US $ 4,210 per QALY gained. The most sensitive parameter was utility of severe thalassemia patients without cardiac complication patients. Conclusion At a societal willingness to pay of 1 GDP per capita, RI-HSCT was a cost-effective treatment for adolescent and young adult with severe thalassemia in Thailand compared to BT-ICT.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results